Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Xiaoshuai ZhangNa XuYunfan YangHai LinBingcheng LiuXin DuXiaoli LiuRong LiangChunyan ChenJian HuangHuanling ZhuLing PanXiaodong WangGuohui LiZhuogang LiuYanqing ZhangZhenfang LiuJianda HuChunshui LiuFei LiWei YangLi MengYanqiu HanLi'e LinZhenyu ZhaoChuanqing TuCaifeng ZhengYanliang BaiZeping ZhouSuning ChenHuiying QiuLijie YangXiuli SunHui SunLi ZhouZelin LiuDanyu WangJianxin GuoLiping PangQingshu ZengXiaohui SuoWeihua ZhangYuanjun ZhengYanli ZhangWeiming LiQian JiangPublished in: Clinical lymphoma, myeloma & leukemia (2024)
Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.